On July 17, 2020, ATOX Signed MOU with Telix Japan to Supply IRE ELiT 68Ge/68Ga Generator for Phase I Study of 68Ga-PSMA-11 Prostate Cancer Diagnostic Imaging Kit
ATOX signed MOU with Telix Pharmaceuticals Japan (hereinafter called Telix Japan) to supply IRE ELiT 68Ge/68Ga generator "Galli Eo ®" for phase I study of Prostate cancer diagnostic imaging.
Combining the 68Ga eluted from the 68Ge/68Ga generator with a compound that accumulates specifically in prostate cancer tissue and then intravenously administering the substance makes it possible to diagnose primary and metastatic prostate cancers using PET. There are high hopes for 68Ga-PSMA as a next-generation diagnostic drug to enable the clear visualization of metastatic cancers that could not be imaged using conventional diagnostic methods.
Telix Pharmaceuticals Japan President Dr. Shintaro Nishimura stated, “Although the clinical utility of PSMA-11 for prostate cancer imaging is well understood worldwide and included in clinical practice guidelines1, to date no meaningful clinical research involving PSMA-11 has been undertaken in Japan. Hence, as Telix Japan plans the first clinical trial of PSMA-11 for prostate cancer imaging in Japan, we are delighted to have established this partnership with ATOX for the provision of the IRE ELiT 68Ge/68Ga-generator. We believe this is a great first step not only for both our companies, but also for prostate cancer patients in Japan.”
ATOX President Toshikazu Yaguchi, added that, “I believe that Telix recognizes ATOX's longstanding contributions to Nuclear Medicine in Japan. ATOX looks forward to working with Telix Japan to ensure the realization of this important clinical trial and to improving the lives of Japanese patients living with prostate cancer.”
About Telix Pharmaceuticals Limited
Telix Pharmaceuticals Japan K.K., is a wholly-owned subsidiary of Telix Pharmaceuticals Limited. Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan and the United States. Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical needs in prostate, kidney and brain cancer. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com.